Skip to main navigation Skip to main content
  • KSPTM
  • E-Submission

PHD : Parasites, Hosts and Diseases

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

5
results for

"Vipa Thanachartwet"

Article category

Keywords

Publication year

Authors

"Vipa Thanachartwet"

Original Articles

Predictive score of uncomplicated falciparum malaria patients turning to severe malaria
Noppadon Tangpukdee, Srivicha Krudsood, Vipa Thanachartwet, Chatnapa Duangdee, Siriphan Paksala, Putza Chonsawat, Siripan Srivilairit, Sornchai Looareesuwan, Polrat Wilairatana
Korean J Parasitol 2007;45(4):273-282.
Published online December 20, 2007
DOI: https://doi.org/10.3347/kjp.2007.45.4.273

In acute uncomplicated falciparum malaria, there is a continuum from mild to severe malaria. However, no mathematical system is available to predict uncomplicated falciparum malaria patients turning to severe malaria. This study aimed to devise a simple and reliable model of Malaria Severity Prognostic Score (MSPS). The study was performed in adult patients with acute uncomplicated falciparum malaria admitted to the Bangkok Hospital for Tropical Diseases between 2000 and 2005. Total 38 initial clinical parameters were identified to predict the usual recovery or deterioration to severe malaria. The stepwise multiple discriminant analysis was performed to get a linear discriminant equation. The results showed that 4.3% of study patients turned to severe malaria. The MSPS = 4.38 (schizontemia) + 1.62 (gametocytemia) + 1.17 (dehydration) + 0.14 (overweight by body mass index; BMI) + 0.05 (initial pulse rate) + 0.04 (duration of fever before admission) - 0.50 (past history of malaria in last 1 year) - 0.48 (initial serum albumin) - 5.66. Based on the validation study in other malaria patients, the sensitivity and specificity were 88.8% and 88.4%, respectively. We conclude that the MSPS is a simple screening tool for predicting uncomplicated falciparum malaria patients turning to severe malaria. However, the MSPS may need revalidation in different geographical areas before utilized at specific places.

Citations

Citations to this article as recorded by  Crossref logo
  • Albumin levels in malaria patients: a systematic review and meta-analysis of their association with disease severity
    Saruda Kuraeiad, Kwuntida Uthaisar Kotepui, Aongart Mahittikorn, Frederick Ramirez Masangkay, Polrat Wilairatana, Apiporn Thinkhamrop Suwannatrai, Kavin Thinkhamrop, Kinley Wangdi, Manas Kotepui
    Scientific Reports.2024;[Epub]     CrossRef
  • Obesity, Diabetes, Plasmodium Infection, and Severe Malaria in Adults: A Systematic Review and Meta-analysis
    Hyelan Lee, Yongyeon Choi, Sangshin Park
    The Journal of Infectious Diseases.2024; 230(6): 1529.     CrossRef
  • Prevalence of Signs of Severity Identified in the Thai Population with Malaria: A Systematic Review and Meta-Analysis
    Wanida Mala, Polrat Wilairatana, Chutharat Samerjai, Frederick Ramirez Masangkay, Kwuntida Uthaisar Kotepui, Manas Kotepui
    International Journal of Environmental Research and Public Health.2022; 19(3): 1196.     CrossRef
  • Obesity and Diabetes as Risk Factors for Severe Plasmodium falciparum Malaria: Results From a Swedish Nationwide Study
    Katja Wyss, Andreas Wångdahl, Maria Vesterlund, Ulf Hammar, Saduddin Dashti, Pontus Naucler, Anna Färnert
    Clinical Infectious Diseases.2017; 65(6): 949.     CrossRef
  • Hemoglobin Concentration and Parasitemia on Hospital Admission Predict Risk of Multiple Organ Dysfunction Syndrome among Adults with Malaria
    Eduardo Villamor, Emily Walton, Henry Oliveros
    The American Journal of Tropical Medicine and Hygiene.2014; 91(1): 50.     CrossRef
  • Falciparum malaria parasitemia index for predicting severe malaria
    N. TANGPUKDEE, S. KRUDSOOD, S. KANO, P. WILAIRATANA
    International Journal of Laboratory Hematology.2012; 34(3): 320.     CrossRef
  • Neurological involvement in patients with falciparum malaria; frequency and prognostic value
    Mohammad Wasay, Asif Taqi, Huma Aziz, Iqbal Azam, M. Asim Beg
    Clinical Neurology and Neurosurgery.2011; 113(2): 104.     CrossRef
  • Indicators of fatal outcome in severe Plasmodium falciparum malaria: a study in a tertiary–care hospital in Thailand
    Noppadon Tangpukdee, Khin Myat Wai, Sant Muangnoicharoen, Shigeyuki Kano, Nanthaporn Phophak, Janram Tiemprasert, Srivicha Krudsood, Polrat Wilairatana
    Asian Pacific Journal of Tropical Medicine.2010; 3(11): 855.     CrossRef
  • 8,666 View
  • 105 Download
  • Crossref
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand
Srivicha Krudsood, Noppadon Tangpukdee, Sant Muangnoicharoen, Vipa Thanachartwet, Nutthanej Luplertlop, Siripan Srivilairit, Polrat Wilairatana, Shigeyuki Kano, Pascal Ringwald, Sornchai Looareesuwan
Korean J Parasitol 2007;45(2):111-114.
Published online June 20, 2007
DOI: https://doi.org/10.3347/kjp.2007.45.2.111

Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.

Citations

Citations to this article as recorded by  Crossref logo
  • Drug resistance markers in Plasmodium vivax isolates from a Kanchanaburi province, Thailand between January to May 2023
    Thanawat Sridapan, Paweesuda Rattanakoch, Kaewkanha Kijprasong, Suttipat Srisutham, Kristan Alexander Schneider
    PLOS ONE.2024; 19(7): e0304337.     CrossRef
  • Adapted Guidelines for Malaria Case Management in Sudan
    Samah Elhassan, Sahar Khalid Mohamed, Khlood Fathi Hassan Alnaeem, Ahmed Abdulgadir Noureddin, Samah Kamaleldeen Bakrri Abass, Fadwa Mohamed Saad, Technical Advisory Committee
    Sudan Journal of Medical Sciences.2024; 19(4): 531.     CrossRef
  • Plasmodium knowlesi as a model system for characterising Plasmodium vivax drug resistance candidate genes
    Lisa H. Verzier, Rachael Coyle, Shivani Singh, Theo Sanderson, Julian C. Rayner, Paulo Pimenta
    PLOS Neglected Tropical Diseases.2019; 13(6): e0007470.     CrossRef
  • Management of relapsingPlasmodium vivaxmalaria
    Cindy S Chu, Nicholas J White
    Expert Review of Anti-infective Therapy.2016; 14(10): 885.     CrossRef
  • Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review
    Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana
    Annals of the Academy of Medicine, Singapore.2016; 45(7): 303.     CrossRef
  • Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review
    Benjamin J Visser, Rosanne W Wieten, Daniëlle Kroon, Ingeborg M Nagel, Sabine Bélard, Michèle van Vugt, Martin P Grobusch
    Malaria Journal.2014;[Epub]     CrossRef
  • Malaria: an update on current chemotherapy
    Benjamin J Visser, Michèle van Vugt, Martin P Grobusch
    Expert Opinion on Pharmacotherapy.2014; 15(15): 2219.     CrossRef
  • Effectiveness of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax and P. falciparum Malaria in Young Children in Papua New Guinea
    Nicolas Senn, Patricia Rarau, Doris Manong, Mary Salib, Peter Siba, John C. Reeder, Stephen J. Rogerson, Blaise Genton, Ivo Mueller
    Clinical Infectious Diseases.2013; 56(10): 1413.     CrossRef
  • Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria
    Nithya Gogtay, Sridharan Kannan, Urmila M Thatte, Piero L Olliaro, David Sinclair
    Cochrane Database of Systematic Reviews.2013;[Epub]     CrossRef
  • Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan
    Tajeldin M Abdallah, Abdel Aziem A Ali, Mohammed Bakri, Gasim I Gasim, Imad R Musa, Ishag Adam
    Malaria Journal.2012;[Epub]     CrossRef
  • Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana
    Daniel Eibach, Nicolas Ceron, Karanchand Krishnalall, Keith Carter, Guillaume Bonnot, Anne-Lise Bienvenu, Stéphane Picot
    Malaria Journal.2012;[Epub]     CrossRef
  • Coartem®: a decade of patient-centric malaria management
    Kamal Hamed, Heiner Grueninger
    Expert Review of Anti-infective Therapy.2012; 10(6): 645.     CrossRef
  • Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia
    Teferi Eshetu, Nasir Abdo, Kunuz H Bedru, Sintayehu Fekadu, Andreas Wieser, Michael Pritsch, Thomas Löscher, Nicole Berens-Riha
    Malaria Journal.2012;[Epub]     CrossRef
  • Primaquine in vivax malaria: an update and review on management issues
    Deepika Fernando, Chaturaka Rodrigo, Senaka Rajapakse
    Malaria Journal.2011;[Epub]     CrossRef
  • Plasmodium vivax treatments
    Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein
    Current Opinion in Infectious Diseases.2011; 24(6): 578.     CrossRef
  • Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial
    Yi Poravuth, Duong Socheat, Ronnatrai Rueangweerayut, Chirapong Uthaisin, Aung Pyae Phyo, Neena Valecha, B. H. Krishnamoorthy Rao, Emiliana Tjitra, Asep Purnama, Isabelle Borghini-Fuhrer, Stephan Duparc, Chang-Sik Shin, Lawrence Fleckenstein, Lorenz von S
    PLoS ONE.2011; 6(1): e14501.     CrossRef
  • The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
    Quique Bassat, David Joseph Diemert
    PLoS Neglected Tropical Diseases.2011; 5(12): e1325.     CrossRef
  • Confirmed Vivax Resistance to Chloroquine and Effectiveness of Artemether-Lumefantrine for the Treatment of Vivax Malaria in Ethiopia
    Ambachew M. Yohannes, Pascal Ringwald, Awash Teklehaimanot, Yngve Bergqvist
    The American Journal of Tropical Medicine and Hygiene.2011; 84(1): 137.     CrossRef
  • Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries
    Cho Naing, Kyan Aung, Daw-Khin Win, Mak Joon Wah
    Transactions of the Royal Society of Tropical Medicine and Hygiene.2010; 104(11): 695.     CrossRef
  • Artemisinin combination therapy for vivax malaria
    Nicholas M Douglas, Nicholas M Anstey, Brian J Angus, Francois Nosten, Ric N Price
    The Lancet Infectious Diseases.2010; 10(6): 405.     CrossRef
  • The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies
    J. D. Maguire, J. K. Baird
    Annals of Tropical Medicine & Parasitology.2010; 104(4): 283.     CrossRef
  • Application of mobile-technology for disease and treatment monitoring of malaria in the "Better Border Healthcare Programme"
    Pongthep Meankaew, Jaranit Kaewkungwal, Amnat Khamsiriwatchara, Podjadeach Khunthong, Pratap Singhasivanon, Wichai Satimai
    Malaria Journal.2010;[Epub]     CrossRef
  • Resistance to Therapies for Infection byPlasmodium vivax
    J. Kevin Baird
    Clinical Microbiology Reviews.2009; 22(3): 508.     CrossRef
  • 8,406 View
  • 100 Download
  • Crossref
Minor liver profile dysfunctions in Plasmodium vivax, P. malariae and P. ovale patients and normalization after treatment
Noppadon Tangpukdee, Vipa Thanachartwet, Srivicha Krudsood, Nutthanej Luplertlop, Karnchana Pornpininworakij, Kobsiri Chalermrut, Sasikarn Phokham, Shigeyuki Kano, Sornchai Looareesuwan, Polrat Wilairatana
Korean J Parasitol 2006;44(4):295-302.
Published online December 20, 2006
DOI: https://doi.org/10.3347/kjp.2006.44.4.295

Liver function tests were performed in 61 vivax, 54 malariae and 15 ovale malaria patients who were admitted to Bangkok Hospital for Tropical Diseases between 2001 and 2004. The
objective
of the study was to evaluate changes in hepatic biochemical indices before and after treatment with artemisinin derivatives. On admission and prior to treatment, hepatic dysfunction was found among the 3 groups. Serum liver function tests and physical examinations were performed weekly during the 28-day follow-up period. Initially elevated serum bilirubin and diminished albumin returned to normal within 2 weeks of treatment. Serum alkaline phosphatase and aminotransferases returned to within normal limits within 3 weeks. We conclude that patients with Plasmodium vivax, P. malariae and P. ovale infections had slightly elevated serum bilirubin, aminotransferase and alkaline phosphatase levels, and hypoalbuminemia. These minor abnormalities returned to normal within a few weeks after treatment with therapies based on artemisinin derivatives.

Citations

Citations to this article as recorded by  Crossref logo
  • The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study
    John Woodford, G. Dennis Shanks, Paul Griffin, Stephan Chalon, James S. McCarthy
    The American Journal of Tropical Medicine and Hygiene.2018; 98(4): 1113.     CrossRef
  • Liver injury in uncomplicated malaria: an overlooked phenomenon
    Brioni R. Moore
    EBioMedicine.2018; 37: 15.     CrossRef
  • Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection
    Sandipan Ray, Sandip K. Patel, Apoorva Venkatesh, Gangadhar Chatterjee, Naziya N. Ansari, Nithya J. Gogtay, Urmila M. Thatte, Prajakta Gandhe, Santosh G. Varma, Swati Patankar, Sanjeeva Srivastava
    Scientific Reports.2017;[Epub]     CrossRef
  • Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission
    Paul Griffin, Cielo Pasay, Suzanne Elliott, Silvana Sekuloski, Maggy Sikulu, Leon Hugo, David Khoury, Deborah Cromer, Miles Davenport, Jetsumon Sattabongkot, Karen Ivinson, Christian Ockenhouse, James McCarthy, Photini Sinnis
    PLOS Neglected Tropical Diseases.2016; 10(12): e0005139.     CrossRef
  • Clinico-pathological studies of Plasmodium falciparum and Plasmodium vivax — malaria in India and Saudi Arabia
    Wajihullah Khan, Haytham Zakai, Umm-e-Asma
    Acta Parasitologica.2014;[Epub]     CrossRef
  • Association of Heme Oxygenase 1 with the Restoration of Liver Function after Damage in Murine Malaria by Plasmodium yoelii
    Sumanta Dey, Somnath Mazumder, Asim Azhar Siddiqui, M. Shameel Iqbal, Chinmoy Banerjee, Souvik Sarkar, Rudranil De, Manish Goyal, Samik Bindu, Uday Bandyopadhyay, J. H. Adams
    Infection and Immunity.2014; 82(8): 3113.     CrossRef
  • A STUDY OF CLINICAL PROFILE IN PATIENTS WITH P.VIVAX MALARIA
    Apte S., Jain J., Parmar A., Apte A., Sinha U, Chanchlani R
    Journal of Evolution of Medical and Dental Sciences.2014; 03(03): 575.     CrossRef
  • Mice lacking inducible nitric oxide synthase develop exacerbated hepatic inflammatory responses induced by Plasmodium berghei NK65 infection
    Onésia Cristina Oliveira-Lima, Danielle Bernardes, Mauro Cunha Xavier Pinto, Rosa Maria Esteves Arantes, Juliana Carvalho-Tavares
    Microbes and Infection.2013; 15(13): 903.     CrossRef
  • Clinico-laboratory profile of severe Plasmodium vivax malaria in a tertiary care centre in Kolkata
    Sayantan Ray, Manjari Saha, Debojyoti Sarkar, Arunansu Talukdar, Amitava Chakraborty
    Tropical Parasitology.2013; 3(1): 53.     CrossRef
  • Effect of artesunate based combination therapy with homeopathic medicine china on liver and kidney of Plasmodium berghei infected mice
    A. Rajan, U. Bagai, S. Chandel
    Journal of Parasitic Diseases.2012;[Epub]     CrossRef
  • A Case of Plasmodium ovale Malaria Imported from West Africa
    SeJin Moon, Baek-Nam Kim, Eun-Young Kuak, Tae Hee Han
    Laboratory Medicine Online.2012; 2(1): 51.     CrossRef
  • Retrospective analysis of vivax malaria patients presenting to tertiary referral centre of Uttarakhand
    Saurabh Srivastava, Sohaib Ahmad, Nadia Shirazi, Sanjiv Kumar Verma, Prashant Puri
    Acta Tropica.2011; 117(2): 82.     CrossRef
  • Ictericia y hepatopatía en el paciente con malaria
    Ana del Mar Cortina, Alberto Tobón
    Infectio.2010; 14(4): 277.     CrossRef
  • Clinical Features of Children Hospitalized with Malaria—A Study from Bikaner, Northwest India
    Dhanpat Kumar Kochar, Ashish Das, Shilpi Garg, Sanjay Kumar Kochar, Ghanshyam Singh Sengar, Gajanand Singh Tanwar, Anjana Gupta, Abhishek Kochar, Deepak Pakalapati, Vishal Saxena, Poonam Chand Khatri, Sheetal Middha, Jyoti Acharya
    The American Journal of Tropical Medicine and Hygiene.2010; 83(5): 981.     CrossRef
  • Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria
    Sue Jean Lee, Rose McGready, Christine Fernandez, Kasia Stepniewska, Moo Koo Paw, Samuel Jacher Viladpai-nguen, Kyaw Lay Thwai, Leopoldo Villegas, Pratap Singhasivanon, Brian M. Greenwood, Nicholas J. White, François Nosten
    European Journal of Clinical Pharmacology.2008; 64(10): 987.     CrossRef
  • Bilirubin inhibits Plasmodium falciparum growth through the generation of reactive oxygen species
    Sanjay Kumar, Mithu Guha, Vinay Choubey, Pallab Maity, Kumkum Srivastava, Sunil K. Puri, Uday Bandyopadhyay
    Free Radical Biology and Medicine.2008; 44(4): 602.     CrossRef
  • 8,391 View
  • 132 Download
  • Crossref
Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand
Srivicha Krudsood, Polrat Wilairatana, Noppadon Tangpukdee, Kobsiri Chalermrut, Siripun Srivilairit, Vipa Thanachartwet, Sant Muangnoicharoen, Natthanej Luplertlop, Gary M. Brittenham, Sornchai Looareesuwan
Korean J Parasitol 2006;44(3):221-228.
Published online September 20, 2006
DOI: https://doi.org/10.3347/kjp.2006.44.3.221

We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.

Citations

Citations to this article as recorded by  Crossref logo
  • Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency
    Huaie Liu, Weilin Zeng, Pallavi Malla, Chengqi Wang, Seetha Lakshmi, Kami Kim, Lynette Menezes, Zhaoqing Yang, Liwang Cui
    Infection.2023; 51(1): 213.     CrossRef
  • Plasmodium cynomolgi in humans: current knowledge and future directions of an emerging zoonotic malaria parasite
    Loick P. Kojom Foko, Amit Kumar, Joseph Hawadak, Vineeta Singh
    Infection.2023; 51(3): 623.     CrossRef
  • The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients
    Ziyu Zhang, Qinhui Li, Xiaoyan Shen, Lankai Liao, Xia Wang, Min Song, Xi Zheng, Yulian Zhu, Yong Yang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
    Germana Bancone, Cindy S. Chu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Targeting Gametocytes of the Malaria Parasite Plasmodium falciparum in a Functional Genomics Era: Next Steps
    Jyotsna Chawla, Jenna Oberstaller, John H. Adams
    Pathogens.2021; 10(3): 346.     CrossRef
  • Recent Advances in Transmission-Blocking Drugs for Malaria Elimination
    Ishan Wadi, Mahendra Nath, Anupkumar R Anvikar, Pargat Singh, Abhinav Sinha
    Future Medicinal Chemistry.2019; 11(23): 3047.     CrossRef
  • G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients
    Sara Avalos, Rosa E. Mejia, Engels Banegas, Cesar Salinas, Lester Gutierrez, Marcela Fajardo, Suzeth Galo, Alejandra Pinto, Angel Mejia, Gustavo Fontecha
    Malaria Journal.2018;[Epub]     CrossRef
  • A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications
    Hazem Elewa, Kyle John Wilby
    European Journal of Drug Metabolism and Pharmacokinetics.2017; 42(5): 745.     CrossRef
  • Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies
    Olalekan A. Uthman, Patricia M. Graves, Rachel Saunders, Hellen Gelband, Marty Richardson, Paul Garner
    Malaria Journal.2017;[Epub]     CrossRef
  • Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond
    Ken Ing Cherng Ong, Hodaka Kosugi, Sophea Thoeun, Hitomi Araki, Moe Moe Thandar, Moritoshi Iwagami, Bouasy Hongvanthong, Paul T Brey, Shigeyuki Kano, Masamine Jimba
    BMJ Global Health.2017; 2(3): e000415.     CrossRef
  • Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review
    Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana
    Annals of the Academy of Medicine, Singapore.2016; 45(7): 303.     CrossRef
  • Enantioselective Pharmacokinetics of Primaquine in Healthy Human Volunteers
    Babu L Tekwani, Bharathi Avula, Rajnish Sahu, Narayan D Chaurasiya, Shabana I Khan, Surendra Jain, Pius S Fasinu, H.M.T. Bandara Herath, Donald Stanford, N.P. Dhammika Nanayakkara, James D McChesney, Travis W Yates, Mahmoud A ElSohly, Ikhlas A Khan, Larry
    Drug Metabolism and Disposition.2015; 43(4): 571.     CrossRef
  • “Recycling” Classical Drugs for Malaria
    Cátia Teixeira, Nuno Vale, Bianca Pérez, Ana Gomes, José R. B. Gomes, Paula Gomes
    Chemical Reviews.2014; 114(22): 11164.     CrossRef
  • KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro
    Anne-Marie Zeeman, Sandra M. van Amsterdam, Case W. McNamara, Annemarie Voorberg-van der Wel, Els J. Klooster, Alexander van den Berg, Edmond J. Remarque, David M. Plouffe, Geert-Jan van Gemert, Adrian Luty, Robert Sauerwein, Kerstin Gagaring, Rachel Borb
    Antimicrobial Agents and Chemotherapy.2014; 58(3): 1586.     CrossRef
  • Novel approaches in antimalarial drug discovery
    Jana Held, Andrea Kreidenweiss, Benjamin Mordmüller
    Expert Opinion on Drug Discovery.2013; 8(11): 1325.     CrossRef
  • Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
    Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran
    Cochrane Database of Systematic Reviews.2013;[Epub]     CrossRef
  • Effects of Antimalarial Molecules on the Gametocyte Stage of Plasmodium falciparum: The Debate
    Odile Dechy-Cabaret, Françoise Benoit-Vical
    Journal of Medicinal Chemistry.2012; 55(23): 10328.     CrossRef
  • Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal
    Tiago Rodrigues, Miguel Prudêncio, Rui Moreira, Maria M. Mota, Francisca Lopes
    Journal of Medicinal Chemistry.2012; 55(3): 995.     CrossRef
  • PharmGKB summary
    Ellen M. McDonagh, Caroline F. Thorn, José M. Bautista, Ilan Youngster, Russ B. Altman, Teri E. Klein
    Pharmacogenetics and Genomics.2012; 22(3): 219.     CrossRef
  • New approaches in antimalarial drug discovery and development: a review
    Anna Caroline C Aguiar, Eliana MM da Rocha, Nicolli B de Souza, Tanos CC França, Antoniana U Krettli
    Memórias do Instituto Oswaldo Cruz.2012; 107(7): 831.     CrossRef
  • Plasmodium vivax treatments
    Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein
    Current Opinion in Infectious Diseases.2011; 24(6): 578.     CrossRef
  • Feeding the Antimalarial Pipeline
    Martin Schlitzer, Regina Ortmann
    ChemMedChem.2010; 5(11): 1837.     CrossRef
  • Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination
    Timothy N.C. Wells, Jeremy N. Burrows, J. Kevin Baird
    Trends in Parasitology.2010; 26(3): 145.     CrossRef
  • Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials
    Anthony E. Kiszewski
    Pharmaceuticals.2010; 4(1): 44.     CrossRef
  • Medications and Glucose-6-Phosphate Dehydrogenase Deficiency
    Ilan Youngster, Lidia Arcavi, Renata Schechmaster, Yulia Akayzen, Hen Popliski, Janna Shimonov, Svetlana Beig, Matitiahu Berkovitch
    Drug Safety.2010; 33(9): 713.     CrossRef
  • A pre-emptive strike against malaria's stealthy hepatic forms
    Dominique Mazier, Laurent Rénia, Georges Snounou
    Nature Reviews Drug Discovery.2009; 8(11): 854.     CrossRef
  • Resistance to Therapies for Infection byPlasmodium vivax
    J. Kevin Baird
    Clinical Microbiology Reviews.2009; 22(3): 508.     CrossRef
  • 8-Aminoquinolines: future role as antiprotozoal drugs
    Babu L Tekwani, Larry A Walker
    Current Opinion in Infectious Diseases.2006; 19(6): 623.     CrossRef
  • 9,865 View
  • 110 Download
  • Crossref
Case Report
Peripheral gangrene in patients with severe falciparum malaria: report of 3 cases
Vipa Thanachartwet, Srivicha Krudsood, Polrat Wilairatana, Weerapong Phumratanaprapin, Udomsak Silachamroon, Sornchai Looareesuwan
Korean J Parasitol 2006;44(2):139-143.
Published online June 20, 2006
DOI: https://doi.org/10.3347/kjp.2006.44.2.139

Peripheral gangrene, characterized by distal ischemia of the extremities, is a rare complication in patients with falciparum malaria. Patients with this complication have generally undergone early amputation of the affected areas. In this report, we describe 3 adult Thai patients presented at the Hospital for Tropical Diseases, Bangkok, with high grade of fever ranged 6-9 days, jaundice, acute renal failure, respiratory failure, alteration of consciousness and shock. Two patients had gangrene developed at the lower extremities on day 1 of hospitalization and 1 patient had gangrene developed on day 3. Blood smears revealed hyperparasitemia with Plasmodium falciparum. These patients were diagnosed as having severe malaria with peripheral gangrene. The resolution of gangrene was successfully achieved by treatment with artesunate and conservative treatment in 2 of 3 cases.

Citations

Citations to this article as recorded by  Crossref logo
  • Symmetrical peripheral gangrene in an atypical case of Plasmodium falciparum malaria with HIV coinfection
    Bishakha Swain, Saurabh Kumar Singh, Uday Raj Singh
    Indian Journal of Medical Sciences.2023; 75: 88.     CrossRef
  • Acute Peripheral and/or Cutaneous Ischemic Syndrome
    Mittermayer B. Santiago, Adriane Paz
    JCR: Journal of Clinical Rheumatology.2021; 27(2): 73.     CrossRef
  • Disseminated intravascular coagulation presenting as symmetrical peripheral gangrene: a case report
    Vineet Jain, Khan Afreen, Jyotsana Kumari, Tanveer Mir, Bilal Wani, Romit Bhushan
    Journal of Medical Case Reports.2019;[Epub]     CrossRef
  • Symmetrical Peripheral Gangrene Complicating Vivax Malaria
    Krishnarpan Chatterjee, Chetana Sen
    Indian Journal of Vascular and Endovascular Surgery.2015; 2(4): 166.     CrossRef
  • Malaria-associated peripheral gangrene
    Deborah B. Martins, Vanda Amado, Stella Langa, Joyce Ventura, Atanasio Taela, Daniel A. DeUgarte
    Journal of Pediatric Surgery Case Reports.2014; 2(9): 417.     CrossRef
  • Plasmodium falciparumMalaria Complicated by Symmetrical Peripheral Gangrene, Bowel Ischemia, Repeated Candidemia, and Bacteraemia
    Emeline Masse, Philippe Hantson
    Case Reports in Medicine.2014; 2014: 1.     CrossRef
  • Peripheral gangrene in an 18-month-old boy withPlasmodium vivaxmalaria
    J Raghunandan, K Rajeshwari, A P Dubey, T Singh
    Paediatrics and International Child Health.2012; 32(3): 164.     CrossRef
  • 9,586 View
  • 63 Download
  • Crossref